L7 Informatics has partnered with Cognate BioServices, a commercial-ready contract development and manufacturing organization (CDMO) in the cell and gene therapy industry, to deploy L7|ESP (Enterprise Science Platform) and implement an integrated manufacturing and lab system. Specifically, L7 will provide Cognate BioServices with a unified data and process automation platform covering manufacturing, quality control, clinical operations, and real-time process intelligence products powered by Microsoft PowerBI.
 
L7|ESP offers an end-to-end solution for the regulatory compliant automation of ATMP manufacturing and quality control operations from original source samples to final Drug Products including the integration of bio-process equipment and quality control instruments.
 
“As a premier solution provider in the cell and gene therapy space, we are honored that Cognate chose L7|ESP to support their efforts towards digitalization across the enterprise,” said Vasu Rangadass, chief executive officer, L7 Informatics. “This decision speaks to their commitment to providing the highest quality cell and gene therapy products at commercial scale to their clients.”
 
J. Kelly Ganjei, chairman and chief executive officer, Cognate BioServices, said, “We are excited to partner with L7 on the development of a fully integrated application that is both a flexible and comprehensive solution for the complexities of cell and gene therapy manufacturing. ESP’s ability to flexibly host many CDMO workflows and easily add new ones as we bring on new clients and new processes is critical for us. Together with L7, we are well-positioned to support digitalization and system unification for research, manufacturing, and clinical operations.”